Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Cancer Res. 2011 Feb 9;71(7):2445–2454. doi: 10.1158/0008-5472.CAN-10-2628

Figure 3.

Figure 3

iNOS is required for rejection of intraocular Ad5E1 clone 2.1 tumors. A, BMDMs were activated with rmIFN-γ plus LPS and used as effector cells in vitro. Cultures were incubated for 48 hours and then harvested. iNOS was inhibited by the addition of 1 or 5 mmol/L L-NAME to activated BMDMs. D-NAME, a biologically inactive isomer of L-NAME, was used as a control. B, WT mice were injected i.p. with L-NAME daily. Controls consisted of C57BL/6 mice injected i.p. with D-NAME daily or left untreated. All C57BL/6 mice were injected in the AC with clone 2.1 tumor cells.